J 2022

Study of Biological Activities and ADMET-Related Properties of Novel Chlorinated N-arylcinnamamides

STRHARSKY, Tomas, Dominika PINDJAKOVA, Jiří KOS, Lucia VRABLOVA, Hana MICHNOVA et. al.

Základní údaje

Originální název

Study of Biological Activities and ADMET-Related Properties of Novel Chlorinated N-arylcinnamamides

Autoři

STRHARSKY, Tomas (203 Česká republika), Dominika PINDJAKOVA, Jiří KOS (203 Česká republika, domácí), Lucia VRABLOVA, Hana MICHNOVA (203 Česká republika), Jan HOSEK (203 Česká republika), Nicol STRAKOVA (203 Česká republika), Veronika LELAKOVA (203 Česká republika), Lenka LEVA (203 Česká republika), Lenka KAVANOVA (203 Česká republika), Michal ORAVEC (203 Česká republika), Alois CIZEK (203 Česká republika) a Josef JAMPILEK (203 Česká republika)

Vydání

International Journal of Molecular Sciences, Basel, MDPI, 2022, 1422-0067

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.600

Kód RIV

RIV/00216224:14110/22:00125675

Organizační jednotka

Lékařská fakulta

UT WoS

000775429300001

Klíčová slova anglicky

cinnamamides; antimicrobial activity; cytotoxicity; lipophilicity; structure-activity relationships

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 19. 4. 2022 09:25, Mgr. Tereza Miškechová

Anotace

V originále

A series of eighteen 4-chlorocinnamanilides and eighteen 3,4-dichlorocinnamanilides were designed, prepared and characterized. All compounds were evaluated for their activity against gram-positive bacteria and against two mycobacterial strains. Viability on both cancer and primary mammalian cell lines was also assessed. The lipophilicity of the compounds was experimentally determined and correlated together with other physicochemical properties of the prepared derivatives with biological activity. 3,4-Dichlorocinnamanilides showed a broader spectrum of action and higher antibacterial efficacy than 4-chlorocinnamanilides; however, all compounds were more effective or comparable to clinically used drugs (ampicillin, isoniazid, rifampicin). Of the thirty-six compounds, six derivatives showed submicromolar activity against Staphylococcus aureus and clinical isolates of methicillin-resistant S. aureus (MRSA). (2E)-N-[3,5-bis(trifluoromethyl)phenyl]- 3-(4-chlorophenyl)prop-2-enamide was the most potent in series 1. (2E)-N-[3,5-bis(Trifluoromethyl)phenyl]-3-(3,4-dichlorophenyl)prop-2-enamide, (2E)-3-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]prop-2-enamide, (2E)-3-(3,4-dichloro- phenyl)-N-[4-(trifluoromethyl)phenyl]prop-2-enamide and (2E)-3-(3,4-dichlorophenyl)- N-[4-(trifluoromethoxy)phenyl]prop-2-enamide were the most active in series 2 and in addition to activity against S. aureus and MRSA were highly active against Enterococcus faecalis and vancomycin-resistant E. faecalis isolates and against fast-growing Mycobacterium smegmatis and against slow-growing M. marinum, M. tuberculosis non-hazardous test models. In addition, the last three compounds of the above-mentioned showed insignificant cytotoxicity to primary porcine monocyte-derived macrophages.

Návaznosti

90123, velká výzkumná infrastruktura
Název: CzeCOS III